🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

RecruitingPhase 2Ages 20 Years - 100 YearsAllKoo Foundation Sun Yat-Sen Cancer Center
NCT06461182 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma. * Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group. * Able to lie flat for at least 30 minutes. * Signing the subject consent form. * ECOG grade 0-2. * The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution. Exclusion Criteria: * Pregnant woman * Severe renal impairment (eGRF\< 30ml/min) * Known or suspected allergy to radiopharmaceuticals * Concurrent or previous diagnosis of malignancies other than lymphoma * Inability to undergo the necessary PET scan procedure * Refusal or unwillingness to sign the informed consent form * Severe medical conditions (severe disabilities, mental disorders)
💊

What it tests

  • Ga-68-CXCR4
📍

Where

1 site
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy